Recruiting PHASE1 INTERVENTIONAL 4-arm NCT07181369

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria (CHILL-MC)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients With Chronic Inducible Urticaria (Part B)

Sponsor: Granular Therapeutics Limited

Conditions Chronic Inducible Urticaria Cold Urticaria Healthy Subjects Symptomatic Dermographism

Interventions GTX-B001 Normal Saline

Updated 3 times since 2025 Last updated: Jan 28, 2026 Started: Oct 6, 2025 Primary completion: Aug 31, 2027 Completion: Aug 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07181369, this PHASE1 trial focuses on Chronic Inducible Urticaria and Cold Urticaria and remains actively recruiting participants. Sponsored by Granular Therapeutics Limited, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Granular Therapeutics Limited

Data source: Granular Therapeutics Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany